Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 3/20 | 0.38 |
| ▸ | GRM5 | P41594 | 1/20 | 0.37 |
| ▸ | PDE4A | P27815 | 2/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | CA4 | P22748 | 1/20 | 0.32 |
| ▸ | CA6 | P23280 | 1/20 | 0.32 |
| ▸ | CA5A | P35218 | 1/20 | 0.32 |
| ▸ | CA7 | P43166 | 1/20 | 0.32 |
| ▸ | CA9 | Q16790 | 1/20 | 0.32 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.32 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.32 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27828669 | 0.87 | GAA (0.46) | EGFRGRM5LMNAGAARAB9A | |
| SCHEMBL18067375 | 0.85 | ALDH1A1 (0.41) | EGFRGRM5GAACA1CA2 | |
| SCHEMBL14606528 | 0.84 | — | — | |
| SCHEMBL9066979 | 0.83 | LMNA (0.45) | CYP1A2CYP2C19LMNAGAAHTT | |
| SCHEMBL10781217 | 0.82 | — | — | |
| SCHEMBL374336 | 0.82 | — | — | |
| SCHEMBL6987146 | 0.82 | — | — | |
| SCHEMBL18757540 | 0.78 | CXCR4 (0.41) | CYP1A2CA1CA2CA9 | |
| SCHEMBL23028717 | 0.78 | OPRM1 (0.39) | EGFRPDE4ACYP1A2LMNAGAA | |
| SCHEMBL14572429 | 0.78 | EGFR (0.32) | EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117298331-A | Modified trehalose-based hydrogel for wound repair | 上海迪派生物科技有限公司 | 2023-12-29 | — | — | CN | claimed |
| CN-117298331-A | Modified trehalose-based hydrogel for wound repair | 上海迪派生物科技有限公司 | 2023-12-29 | — | — | CN | disclosed |
| CN-116745289-A | Agonists of free fatty acid receptor 1 and their use in diseases associated with said receptor | 奥洛治疗有限公司 | 2023-09-12 | — | — | CN | disclosed |
| US-11034797-B2 | Polyimide precursor composition, use thereof and polyimide made therefrom | ETERNAL MATERIALS CO., LTD. (TW) | 2021-06-15 | — | — | US | disclosed |
| US-20210079161-A1 | POLYIMIDE PRECURSOR COMPOSITION, USE THEREOF AND POLYIMIDE MADE THEREFROM | ETERNAL MATERIALS CO., LTD. (TW) | 2021-03-18 | — | — | US | disclosed |
| US-8193164-B2 | Organic compounds | NOVARTIS AG (CH) | 2012-06-05 | — | — | US | disclosed |
| US-8193164-B2 | Organic compounds | NOVARTIS AG (CH) | 2012-06-05 | — | — | US | disclosed |
| US-20100190784-A1 | Organic Compounds | NOVARTIS AG | 2010-07-29 | — | — | US | disclosed |
| US-20100190784-A1 | Organic Compounds | NOVARTIS AG | 2010-07-29 | — | — | US | disclosed |
| US-5854244-A | Melamine derivatives for use in the treatment of cancer | CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED (GB) | 1998-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100190784-A1 | Organic Compounds | CYP1B1, POLR2A, CYP1A1 | EGFR 3040/4885GRM5 4333/4885PDE4A 2941/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.